ICON Plc 's stock (NASDAQ:ICLR) has reached a 52-week low, dipping to $183.31, as the company navigates through a turbulent market environment. With a market capitalization of $15.19 billion and a P/E ...

Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology ...

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased ICON plc ("ICON" or the "Company") (NASDAQ: ICLR) ordinary shares between ...

The market expects Icon PLC (ICLR) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is ...

ICON Plc ICON is a global provider of outsourced development services that span the entire lifecycle of product development, from compound selection to Phase I-V clinical studies, outcomes research, ...

ICON Public Limited (NASDAQ:ICLR – Get Free Report)’s share price reached a new 52-week low on Thursday after Truist Financial lowered their price target on the stock from $284.00 to $262.00. Truist ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial results for the fourth quarter and full year ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and ...

DUBLIN, January 29, 2025--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial ...